Background
Surgery and chemotherapy are the two most common treatments for cancers, including ovarian cancer. Although most ovarian cancers occur over the age of 45 yr, it may involve younger women and affect their reproductive ability.
Conclusion
The LGR5, FOXO1, and miR-340 genes can be targeted for early diagnosis and more accurate treatment of ovarian cancer and may prevent some of the ovarian cancer complications such as infertility.
Methods
In this case-control study, 30 ovarian cancer samples (with the average age of 37 ±±<math><mo>±</mo></math> 2.5 years) coupled with their non-tumor marginal tissue (as a control) were collected. Proliferated cell lines were treated with several concentrations of cisplatin, and the half maximal inhibitory concentration (IC50) of cisplatin was quantified by MTT-assay. After RNA extraction, cDNA synthesis and qRT-PCR were done. Finally, the
Objective
To assess the expression of Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), Forkhead Box O1 (FOXO1), and miR-340 genes in the ovarian cancer tissues as well as ovarian cancer cell lines. Materials and
Results
While the expression levels of miR-340 and FOXO1 genes in tumor samples displayed a significant reduction (p ≤≤<math><mo>≤</mo></math> 0.001), the LGR5 gene presented a significant increase in expression (p ≤≤<math><mo>≤</mo></math> 0.0001). However, conversely, the expression levels of miR-340 and FOXO1 genes in cisplatin-sensitive cell lines, after 24, 48, and 72 hr of cisplatin treatment, indicated a significant increase (p ≤≤<math><mo>≤</mo></math> 0.001) while the expression of LGR5 gene showed a significant decrease in the cisplatin-sensitive cell line (p <<<math><mo><</mo></math> 0.05).